NFKB1 and Alzheimer disease: Results also demonstrate the pre-treatment with GLE decreases gene expression of CHUK, NFƙB1/p50, and IKBKE, which may be associated with the etiology and neuropathology of AD through activation of NFƙB and MAPK signaling pathways.